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ABSTRACT: Based on hit-likeness and chemical diversity, a number of chalcones and chalcone-mimetic 
compounds were selected as putative Notch inhibitors. The evaluation of the antiproliferative effect com-
bined with the inhibition of Notch1 expression in KOPTK1 cell line identified compound 18, featuring a 
tetrahydronaphthalene-based scaffold, as a new promising Notch-blocking agent.
Notch signaling is an evolutionarily conserved cell communication pathway regulating many biological 
processes including stem cells self-renewal, cell differentiation, proliferation, and survival in different 
tissues during embryonic and adult life.1−3 The mammalian Notch family includes four trans-membrane 
receptors (namely, Notch1−4), and five trans-membrane ligands (namely, Jagged-1 and -2, Delta-like-1, 
-3, and -4). Notch signaling is a short-range intercellular communication system, wherein a membrane-
tethered Notch ligand on the signal-sending cell interacts with a transmembrane Notch receptor on the 
juxtaposed signal-receiving cell.4 This activation induces a series of proteolytic events such as the S2 
cleavage performed by the ADAM metalloproteases, and the S3 cleavage by the gamma secretase (GS) 
complex, which trigger the release of activated intracellular domain of Notch and its translocation to the 
nucleus.5 The subsequent interaction with the DNA binding protein CSL (CBF1/Suppressor of Hair-
less/LAG−1; also known as RBPJ) and Mastermind-like protein (MAML) promotes the transcription of 
Notch downstream target genes.5 Aberrant Notch activation due to either gene mutation or amplification 
or to post-translational modifications has been linked to the onset of different solid and hematological 
 cancers, including T-cell acute lymphoblastic leukemia (T-ALL). Sixty percent of TALL cases are associ-
ated with activating NOTCH1 mutations and function of Notch3.6−8 Moreover, Notch signaling maycon-
tribute to chemotherapy resistance, thus suggesting Notch inhibition as a strategy in anticancer targeted 
therapy.9,10 Notwithstanding, small molecules (e.g., GS inhibitors (GSI) such as MK-0752, RO4929097 
and PF-03084014) and large molecules (e.g., Notch1-specific antibody OMP-52M51) currently in clinical 
development are not effective in all patients and often cause severe side-effects that limit their widespread 
therapeutic use and raise the need for novel Notch-blockingagents.11,12 
Recently, an in-house library of natural products and their derivatives was used as a source of potential 
inhibitors of the Notch signaling in T-ALL.13,14 Eight representative molecules of the library were selected 
through a cheminformatics approach and tested in vitro. The chalcone scaffold emerged as a promising 
tool to inhibit Notch signaling, and in particular, the synthesis of several chalcones combined with their 
biological evaluation highlighted the chalcone 8 as the most potent Notch blocking agent of the series, 
suggesting the synergistic activity of 2′- and 4-hydroxy groups.13,14 Herein, we designed and synthesized 
a number of chalcones and chalconemimetic compounds based on hit-likeness and chemical diversity, and 
we evaluated their antiproliferative activity in KOPTK1 cells. Small molecules able to reduce cell growth 






Chart 1. Chemical structures of chalcone-8 derivatives (1-7) and chalcone mimetics (9-18). 
  
 
Results And Discussion. Synthesis of chalcones and chalcone-mimetic derivatives. The general syn-
thetic approach to efficiently yield chalcone scaffold bearing substituents at different positions (1−7) was 
based on the Claisen−Schmidt condensation as previously reported (Chart 1).13,15 For the synthesis of the 
chalcone mimetics (9−18) (Chart 1), the bicyclic acids (19a−c) were used to perform the Friedel−Crafts 
acylation of some arenes (20a−d) by using two different procedures (Scheme 1). 
The ketone 9 was prepared by the reaction between the activated form of 1,2,3,4-tetrahydronaphthalene-
2-carboxylic acid 19a with 1,3-dimethoxybenzene 20a in the presence of BF3·OEt2. Since the catalyst 
induced the partial demethylation of the methoxy group vicinal to the ketone, the reaction afforded a 
mixture of 9 and 10 with 31% and 42% yields, respectively. Otherwise, performing the reaction with triflic 
acid,16 the ketone 9 was obtained in 70% yield. When resorcinol (20c) was used as the arene, compound 
11 was obtained in 67% yield, so that the heating conditions favor the formation of the C-acylated prod-
uct.17 Removal of the methoxy groups in 9 by using BBr318 led to the formation of a mixture of 12 and 13 
in 39% and 48% yields, respectively. The trimethoxy derivative 14 was obtained in low yield probably 
due to steric hindrance. However, the direct acylation reaction of the fluoroarene 20d with the acid 19a 
by adapting previous reports using TFAA/TfOH,19,20 allowed the formation of the regioisomers 15 and 
16, as shown in Scheme 1. Similarly, reaction of the 7-methoxychromane-3-carboxylic acid 19b or 7-
methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 19c with 20a in the presence of TFAA/TfOH 
afforded the aryl derivatives 17 and 18 in 38% and 73% yield, respectively. In all cases, compounds 9−18 
were obtained as racemates. 
  
 
Conformation of chalcone 8 and chalcone mimetics. E-Chalcones can adopt s-cis or s-trans confor-
mations.21 Nonsubstituted chalcones at the α-position adopt, in general, a s-cis conformation, and this was 
confirmed for the chalcone 8 by 2D-NOESY experiments (Figure S1). The incorporation of a bicyclic 
ring in the structure of the chalcone mimetics (exemplified by compound 12 in Figure 1), where the double 
bond conjugated to the enone has been removed, is meant to restrict the conformational freedom of these 
analogues. The energy minimized conformers (see Computational Methods S20) of the 12-R and 12-S 
enantiomers present in the racemic mixture were constructed and superimposed with the X-ray crystal 
structure of a model s-cis chalcone (that is, benzylidene acetophenone, CCDC 1185311).22 As shown in 
Figure 1, both enantiomers are able to locate the OH-substituent on ring B close to the 4-position of ring 
B in the s-cis chalcone. Thus, the compounds were assayed as racemic mixtures. 
 
Biological Results and Discussion. To evaluate the effectiveness of chalcones 1−7 and chalcone mimet-
ics 9−18, we investigated their growth-inhibitory potency in KOPTK1 T-ALL cell line. These cells are 
sensitive to Notch inhibition by GSI and harbor activating Notch1 gene mutations.7 As we demonstrated 
previously, in this cell line the reference compound 8 inhibited Notch1 signaling and cell growth in the 
concentration range between 1 and 2.5 μM.13 Therefore, we compared the effects of compounds 1−7 and 
9−18 in KOPTK1 cells on the endogenous levels of the activated domain of Notch1 (N1Val) by Western 
blotting and on cell growth by MTS assay, treating the cells with 2.5 μM of each compound for 36 h and 
taking 30% decrease of cell viability as a threshold value for further screening (Figures 2a,b and S2). 
Notably, the comparison of the viability data and the N1Val levels after exposure to all chalcone deriva-
tives confirmed a remarkably positive correlation between N1Val protein levels and the sensitivity of 
KOPTK1 cells to the bioactive compounds 1, 5, 9, 12, and 18 indicating that their antiproliferative effects 
were tightly associated with Notch signaling inhibition (Figure 2c). Further proving Notch inhibition, 
selected compounds decreased the N1Val protein expression and the endogenous mRNA levels of the 
Notch target gene DELTEX1 (DTX1). Interestingly, among them, only compounds 1 and 18 showed 
Notch1-inhibitory effects comparable to that of compound 8, whereas the Notch inhibition exerted by 5, 
9, and 12 was weaker than that of compound 8 (Figures 2d and S3). In addition, we determined the half-
maximal growth-inhibitory concentration (IC50) in a dose−response proliferation assay with increasing 
concentrations (namely, 0, 0.5, 1, 2.5, 5, 10, 20, and 50 μM) of selected compounds 1, 5, 9, 12, and 18. 
These molecules inhibited leukemic cell growth to a similar extent each other, with IC50 values compara-
ble to that of the reference compound 8 and ranging from 0.7 to 3.8 μM (Figure 2e). Notably, statistical 
Figure 1. Superposition of the crystal structure of benzyli-
dene acetophenone (green) with energy minimized conform-
ers of 12-S (magenta) and 12-R (yellow). Atom pairs used for 
the superimposition are indicated with black arrows. 
 analysis of single-point comparative treatment showed no significant differences in the inhibition of cell 
growth between compounds 8, 1, 9, and 18, which provided a comparable effect at 2.5 μM concentration. 
The slightly higher IC50 values of 5 and 12 are in line with their weaker effect on Notch1 inhibition 
(Figures 2a,d and S3). Determination of the IC50 value for compound 1 was not possible due to the irreg-
ular shape of its growth inhibition curve (Figure S4). Moreover, consistent with the effect induced by 
chalcone 8 in G1-phase cell cycle arrest and apoptosis,13 we found that growth inhibition by 1 was ac-
companied by both increased levels of the antiproliferative factor p27kip and of the apoptotic marker 
cleaved poly ADP-ribose polymerase (CL PARP). On the contrary, the most promising chalcone mimetics 
9 and 18 failed to upregulate p27kip and promoted the highest levels of PARP cleavage among tested 
compounds (Figure 2f), whereas the weakest Notch inhibitors 5 and 12 induced p27kip without affecting 
PARP processing (Figure 2f). Finally, chalcone mimetics 9 and 18 affected cell proliferation also in 
GSIresistant JURKAT cell line23 and in immortalized nontumorigenic human keratinocyte HaCat cells in 
which Notch signaling acts as an onco-suppressor.24 These latter observations suggest different mecha-
nisms of action and/or off-target effects by chalcones and chalcone mimetics (Figure S5). 
 
  
Figure 2. Antiproliferative and molecular effects of chalcones and chalcone-like derivatives in KOPTK1 T-ALL cells. (a) 
Protein expression levels of activated domain of Notch1 (N1Val) in KOPTK1 cells treated for 36 h with 2.5 μM of compounds 
1−18 or vehicle alone (DMSO). β-Actin is used as loading control. (b) Histogram shows the mean of relative cell viability of 
KOPTK1 cells treated with 2.5 μM of compounds 1−18 or DMSO for 36 h measured with MTS assay ± SEM obtained from 
two independent experiments performed in triplicate. ****P < 0.0001, comparing with DMSO. (c) Representative graph show-
ing the results of Pearson’s correlation test between the average values of relative N1Val expression obtained with optical 
densitometry and cell viability in KOPTK1 treated with compounds 1−18 vs DMSO. R = 0.9535, R2 = 0.90925, p < 0.0001. 
(d) N1Val and β-actin protein expression levels (lower panel) and DELTEX1 (DTX1) relative gene expression levels (upper 
panel) in KOPTK1 cells treated with 2.5 μM of compounds 8, 1, 5, 9, 12, and 18 or vehicle alone (DMSO) for 36 h. Data 
represent mean values for three independent experiments performed in triplicate ± SEM. (e) IC50 values of compounds 8, 1, 
5, 9, 12, and 18 determined in KOPTK1 after 36 h of incubation. Data represent mean values for three independent experiments 
performed in triplicate ± SD. (f) Protein expression of p27kip and of the nonprocessed PARP (FL PARP) and its cleaved form 




 SAR of Chalcones and Chalcone-mimetic Derivatives as Notch Inhibitors. Structure−activity relationships 
(SAR) of a previous series of chalcone derivatives revealed how the 2′- and 4-hydroxy groups are essential 
for both cell proliferation and Notch inhibition.13 The biological results obtained with the chalcones de-
scribed in this work confirmed the previous SAR. Accordingly, the effectiveness of the chalcones 1 and 
5 on growth inhibition of KOPTK1 T-ALL cell line highlighted the pivotal role of 4-OH substitution to 
ring B (Figure 2b). However, the Western blotting assay on N1Val expression using chalcone 8 as the 
reference compound showed a comparable inhibitory effect just for 1 (Figure 2a). These results reinforced 
the previous evidence also for the ring A showing how the lack of 4-OH substitution led to a weaker 
inhibitory activity toward activated Notch1. The introduction of 3-CH3 group at ring B did not influence 
the inhibition of endogenous Notch signaling activity and cell growth. Chalcone mimetics 9, 12, and 18 
proved to decrease the cell viability of KOPTK1 T-ALL cells with IC50 values in the lowup to submi-
cromolar range (Figure 2e). While compound 12, with a substitution pattern at rings A and B similar to 
that of the reference chalcone 8, showed some Notch-inhibitory effects, the best inhibition of Notch1 
intracellular domain in this series was obtained by compound 18 (Figure 2d). Thus, it is interesting to note 
that compounds incorporating a tetrahydronaphthalene scaffold are also able to exert inhibition of the 
Notch pathway, although with some differences compared to chalcones. Conclusion. Based on previous 
evidence and molecular modeling studies, several chalcones 1−7 and chalcone mimetics 9−18 were se-
lected, synthesized, and tested toward antiproliferative activity and Notch inhibition in KOPTK1 TALL 
cells. Compounds 1 and 18 exhibited cell growth reduction combined with inhibition of Notch1 intracel-
lular domain, mostly comparable to the reference compound 8. SAR analysis of the chalcone series con-
firmed the key role played by the 2′- and 4-OH groups on both antiproliferative and Notch1 inhibitory 
activity. However, the introduction of bicyclic ring in the structure of the chalcone mimetics promotes 
Notch inhibition through different biological responses, thus suggesting that more in-depth investigations 
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